Key facts
- This page summarizes Stuart Diamond's Form 4 filing for bioAffinity Technologies, Inc. (BIAF).
- 3 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 02 Dec 2022, 18:12.
Stuart Diamond - 31 Aug 2022 Form 4 Insider Report for bioAffinity Technologies, Inc. (BIAF)
- Reporting relationship
- Director
- Issuer ticker
- BIAF
- Reported as of
- 31 Aug 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 02 Dec 2022, 18:12:22 UTC
- Prior SEC filing
- 02 Dec 2022
- Next SEC filing
- 06 Jul 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Wilhelm E. Liebmann, as attorney-in-fact for Stuart Diamond
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Stuart Diamond filed Form 4 for bioAffinity Technologies, Inc. (BIAF) on 02 Dec 2022.
Change
- Previous filing in this sequence was filed on 02 Dec 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
BIAF
transaction
Common Stock, par value $0.007
Purchase
- Transaction value
- Shares
- +4,081
- Change %
- Price
- Shares after
- 4,081
- Date
- 31 Aug 2022
- Ownership
- Direct
- Footnotes
- F1, F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
BIAF
transaction
Derivative
Warrants (right to buy)
Purchase
- Transaction value
- Shares
- +4,081
- Change %
- Price
- Shares after
- 4,081
- Date
- 31 Aug 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 4,081
- Exercise price
- $7.35
- Footnotes
- F1, F2
BIAF
transaction
Derivative
Non-tradeable Warrants (right to buy)
Purchase
- Transaction value
- Shares
- +4,081
- Change %
- Price
- Shares after
- 4,081
- Date
- 31 Aug 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 4,081
- Exercise price
- $7.66
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The number of securities and exercise prices reported in this Form 4 reflect the 1-for-7 reverse stock split of the common stock, par value $0.007 (the "Common Stock"), of bioAffinity Technologies, Inc. (the "Issuer"), which became effective with the State of Delaware on June 23, 2022 in connection with the Issuer's initial public offering (the "IPO").
Footnote F2
The reported securities are included within 4,081 Units purchased by Mr. Diamond for $6.125 per Unit in the Issuer's IPO. Each Unit consists of one share of Common Stock, one five-year tradeable warrant to purchase one share of Common Stock at an exercise price of $7.35 per share, and one five-year non-tradeable warrant to purchase one share of Common Stock at an exercise price of $7.656 per share.
SEC remarks
Exhibit List - Exhibit 24.1: Power of Attorney (Stuart Diamond)